09:54 AM EST - Lorus Therapeutics Inc. : announced that the Food and Drug Administration completed its review and cleared the company's Investigational New Drug application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma. Lorus Therapeutics Inc.
shares T.LOR are trading up $0.025 at $0.48.
